About Ignyta
Ignyta is a company based in San Diego (United States) founded in 2011 by Gary Firestein was acquired by Roche in December 2017. Ignyta has raised $96.87 million across 9 funding rounds from investors including Roche, Teva Pharmaceuticals and Great Point Partners. Ignyta operates in a competitive market with competitors including TScan Therapeutics, Imbed Biosciences, GigaGen, Shattuck Labs and Boundless Bio, among others.
- Headquarter San Diego, United States
- Founders Gary Firestein
- Stage Public
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ignyta, Inc.
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$13.35 M (USD)67.02as on Mar 31, 2023
-
Net Profit
$1.62 M (USD)27.55as on Mar 31, 2023
-
EBITDA
$2.28 M (USD)25.37as on Mar 31, 2023
-
Total Equity Funding
$96.87 M (USD)
in 9 rounds
-
Latest Funding Round
$160 M (USD), Post-IPO
Oct 20, 2017
-
Investors
Roche
& 4 more
-
Employee Count
Not available
-
Acquired by
Roche
(Dec 21, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ignyta
Ignyta has successfully raised a total of $96.87M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $160 million completed in October 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ignyta
Ignyta has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, Teva Pharmaceuticals and Great Point Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on company buyouts
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Private equity investments are managed by this USA-based firm.
|
Locked | Locked | Locked |
Investor details for Ignyta
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ignyta
Investment portfolio details for Ignyta
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ignyta
Detailed financials for Ignyta
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ignyta Comparisons
Peer comparison for Ignyta
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ignyta
Ignyta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, Imbed Biosciences, GigaGen, Shattuck Labs and Boundless Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
Nanotech-based wound care products are developed and provided.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
An immunotherapy platform for oncology and other diseases is developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer are developed by targeting ecDNA.
|
|
| Locked | Locked | Locked |
T-cell therapies for cancer treatment are developed by Bolt Biotherapeutics.
|
Detailed competitors of Ignyta
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ignyta
Complete news archive for Ignyta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ignyta
Ignyta was founded in 2011.
Ignyta is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Ignyta is a funded company, having raised a total of $96.87M across 9 funding rounds to date.
Annual revenue of Ignyta is $13.35M as on Mar 31, 2023.
Ignyta employs an integrated RxDx strategy of combining highly targeted drug discovery and development with companion diagnostics for patient selection. The main drugs in its pipeline include - Entrectinib (An orally available, selective tyrosine kinase inhibitor), Taladegib (A small molecule hedgehogsmoothened antagonist), RXDX-105 (small-molecule multikinase inhibitor), RXDX-107 (an alkyl ester of bendamustine encapsulated in human serum albumin (HSA) to form nanoparticles). Most of these drugs are at an early clinical stage. On the diagnostic side, Ignyta has launched Trailblaze Pharos, a multiplex assay for identifying actionable gene rearrangements in solid tumors that can be treated with entrectinib.
Ignyta's top competitors include Imbed Biosciences, GigaGen and Shattuck Labs.
Ignyta has 5 investors. Key investors include Roche, Teva Pharmaceuticals, Great Point Partners, City Hill Ventures, and Colt Ventures.